GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Cyclically Adjusted PB Ratio

CLVLF (Clinuvel Pharmaceuticals) Cyclically Adjusted PB Ratio : 5.74 (As of May. 16, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-05-16), Clinuvel Pharmaceuticals's current share price is $6.95. Clinuvel Pharmaceuticals's Cyclically Adjusted Book per Share for the fiscal year that ended in Jun24 was $1.21. Clinuvel Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 5.74.

The historical rank and industry rank for Clinuvel Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

CLVLF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.6   Med: 15.94   Max: 60.33
Current: 6.17

During the past 13 years, Clinuvel Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 60.33. The lowest was 2.60. And the median was 15.94.

CLVLF's Cyclically Adjusted PB Ratio is ranked worse than
84.41% of 667 companies
in the Biotechnology industry
Industry Median: 1.47 vs CLVLF: 6.17

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Clinuvel Pharmaceuticals's adjusted book value per share data of for the fiscal year that ended in Jun24 was $2.692. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.21 for the trailing ten years ended in Jun24.

Shiller PE for Stocks: The True Measure of Stock Valuation


Clinuvel Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.03 37.55 13.85 12.56 8.38

Clinuvel Pharmaceuticals Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 12.56 - 8.38 -

Competitive Comparison of Clinuvel Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Clinuvel Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Clinuvel Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=6.95/1.21
=5.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinuvel Pharmaceuticals's Cyclically Adjusted Book per Share for the fiscal year that ended in Jun24 is calculated as:

For example, Clinuvel Pharmaceuticals's adjusted Book Value per Share data for the fiscal year that ended in Jun24 was:

Adj_Book=Book Value per Share/CPI of Jun24 (Change)*Current CPI (Jun24)
=2.692/128.9064*128.9064
=2.692

Current CPI (Jun24) = 128.9064.

Clinuvel Pharmaceuticals Annual Data

Book Value per Share CPI Adj_Book
201506 0.194 99.838 0.250
201606 0.280 100.859 0.358
201706 0.402 102.809 0.504
201806 0.618 104.945 0.759
201906 0.811 106.617 0.981
202006 1.029 106.246 1.248
202106 1.528 110.332 1.785
202206 1.786 117.112 1.966
202306 2.236 124.170 2.321
202406 2.692 128.906 2.692

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Clinuvel Pharmaceuticals  (OTCPK:CLVLF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Clinuvel Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Clinuvel Pharmaceuticals Headlines

From GuruFocus

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-10-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-09-2022

Letter to shareholders from CLINUVEL's CEO

By GuruFocusNews GuruFocusNews 04-29-2022

CLINUVEL Trial Results Show Drug Reduces DNA Damage

By Stock market mentor Stock market mentor 01-16-2023

CLINUVEL Expands Pharmaceutical Portfolio

By Don Li2 Don Li2 11-08-2021

CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

By Stock market mentor Stock market mentor 02-02-2023

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-30-2022